Reuters logo
BRIEF-Noxxon Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial
May 16, 2017 / 6:14 AM / 5 months ago

BRIEF-Noxxon Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial

May 16 (Reuters) - NOXXON PHARMA NV:

* ANNOUNCES COLLABORATION WITH NATIONAL CENTER FOR TUMOR DISEASES IN HEIDELBERG FOR NOX-A12/KEYTRUDA PHASE 1/2 COMBINATION TRIAL

* CANCER CENTER TO CONDUCT NOXXON TRIAL IN METASTATIC COLORECTAL AND PANCREAS CANCER PATIENTS

* TRIAL IS PART OF COLLABORATION WITH MERCK & CO/MSD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below